BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Three More Biopharma Companies Shuffle Executive Deck

  Three biotech firms announced a change in leadership recently, led by Pardes Biosciences, followed by HUTCHMED and BeiGene. Read the details below.

  March 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Gilead Says Trodelvy Slows Progression of Common Forms of Breast Cancer

  Gilead Sciences posted some good news: a late-stage study of its antibody-drug conjugate Trodelvy shows promise in slowing the progression of the most common forms of breast cancer.

  March 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Astellas One Step Closer to Bringing Nonhormonal Menopause Therapy to Market

  The trial’s primary endpoint was to assess endometrial health, with additional goals of evaluating the safety and tolerability of the drug.

  March 7, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  J&J, Biopharma Turn to China for Innovative Collaborations

  China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.

  March 7, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  FDA

  Opdivo Nets Neoadjuvant Approval in NSCLC while Keytruda Shines in Melanoma

  BMS and Opdivo’s blockbuster checkpoint inhibitor picked up a new regulatory win after the FDA approved the cancer drug in combination with platinum-doublet chemotherapy.

  March 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  COVID-19 Update: Deaths Cross Somber 6 Million Mark, Longterm Cardiovascular Risks

  As state and local governments across the United States begin to lift mitigation efforts, the death toll continues to climb across the globe, a reminder that COVID-19 is still a serious public health concern.

  March 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Genetown

  UPDATED: In Dire Financial Straits, 2022 is Make or Break Year for bluebird bio

  Shares of bluebird bio were falling rapidly in premarket trading Monday morning after the company revealed its dire financial straits over the weekend.

  March 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Alpine Cancer Drug Hit with Partial Hold after Patient Death

  The FDA clinical hold comes after Alpine reported a patient died during the NEON-2 trial.

  March 7, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Three New Collaborations Inked to Advance New Therapies, Vaccines

  Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.

  March 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Three Influential Women in Biopharma Explain How to Break the Executive Barrier

  According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.

  March 7, 2022

   · 

  9 min read

   · 

  Abbey Glasure